Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
Convergent Therapeutics has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in September 2024.
Convergent Therapeutics's investors include OrbiMed, RA Capital Management, Novo Holdings, Invus.
Convergent Therapeutics is headquartered in Cambridge, United States.
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
Convergent Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Convergent Therapeutics — Funding & Investors." VCBacked, September 24, 2024, https://www.vcbacked.co/company/convergent-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Convergent Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/convergent-therapeutics
{{cite web |title=Convergent Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/convergent-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated